| Literature DB >> 22175027 |
Victor D Martinez1, Daiana D Becker-Santos, Emily A Vucic, Stephen Lam, Wan L Lam.
Abstract
Arsenic is a potent human carcinogen. Around one hundred million people worldwide have potentially been exposed to this metalloid at concentrations considered unsafe. Exposure occurs generally through drinking water from natural geological sources, making it difficult to control this contamination. Arsenic biotransformation is suspected to have a role in arsenic-related health effects ranging from acute toxicities to development of malignancies associated with chronic exposure. It has been demonstrated that arsenic exhibits preference for induction of squamous cell carcinomas in the human, especially skin and lung cancer. Interestingly, keratins emerge as a relevant factor in this arsenic-related squamous cell-type preference. Additionally, both genomic and epigenomic alterations have been associated with arsenic-driven neoplastic process. Some of these aberrations, as well as changes in other factors such as keratins, could explain the association between arsenic and squamous cell carcinomas in humans.Entities:
Year: 2011 PMID: 22175027 PMCID: PMC3235812 DOI: 10.1155/2011/454157
Source DB: PubMed Journal: J Skin Cancer ISSN: 2090-2913
Figure 1Carcinogenic mechanisms of arsenic transformation. Ingested arsenic undergoes a biotransformation process. (1) Biotransformation could lead to arsenic excretion, when conjugated with glutathione. (2) Biotransformation generates reactive oxygen species (ROS), namely, superoxide anions (O2 −), hydrogen peroxide (H2O2), hydroxyl radicals (OH), that induce single-strand (ssDNA) and double-strand (dsDNA) breaks by inducing oxidative damage. The process can also inhibit DNA break repair mechanisms for ssDNA breaks (base excision repair (BER)) and for dsDNA breaks (homologous recombination (HR) and/or nonhomologous end joining (NHEJ)). Additionally, ROS derived from arsenic biotransformation can act as cocarcinogens, for example, increasing damage potential of ultraviolet (UV) light. Furthermore, the requirement of S-adenosyl methionine (SAM) for arsenic biotransformation can lead to depletion of SAM, which is the substrate for DNA methylation.
Studies exhibiting associations between arsenic exposition and cell types of lung cancer.
| Location | Number of lung cancer cases | Cell type | Smoking status | Calculated risk | Dosage | Reference |
|---|---|---|---|---|---|---|
| Britain | 6 cases treated with Fowler's solution or potassium arsenite (2 male/4 female) | (i) 5 undifferentiated carcinomas | 3 never smokers, 1 smoker | NA | NA | [ |
|
| ||||||
| Taiwan | (i) 76 LC cases (50 males/36 females) | (i) Male cases: 40% SqCC, 38% AdC, 22% others | NA | Odds ratios for developing LC were 3.39 for whom used well water from arsenic-contaminated zones during 40 or more years, | Median of 780 | [ |
|
| ||||||
| Japan: Niigata Prefecture | (i) 443 individuals exposed to arsenic | (i) 3 SCC | All smokers, except for female case | SMR = 15.6 for developing LC among individuals ( | [ | |
|
| ||||||
| Southwest and northeast Taiwan | 139 newly diagnosed LC cases from a BFD endemic zone | (i) 45% SqCC | (i) 31.9% never smokers | Relative risk according to exposure group | Average arsenic level in groundwater ( | [ |
|
| ||||||
| Taiwan | National Cancer Registration Program with 37.290 LC patients (26.850 men/10.440 women | Men†
| NA | Male and female patients from | (i) Towns in BFD | [ |
|
| ||||||
| Bangladesh | (i) 3.223 (2811 male) with a primary LC | 50.5% and 39.0% of SqCC among smokers and nonsmokers, respectively | (i) 79.7% smokers | OR = 1.45, | >100 | [ |
|
| ||||||
| Northeastern Taiwan | (i) 8086 residents were followed for 11 years (6888 remained in the final analysis) | (i) 75 (42.1%) SqCC | At enrollment | The RRs and 95% CIs for 100–300 and >300 | The mean (arsenic) among wells with known arsenic concentration was 117.2 | [ |
|
| ||||||
| USA: New Hampshire, Vermont. | (i) 223 lung cancer (100 male/123 female) | 75 cases were SqCC and SCC | Data from cases | Arsenic exposure was associated with SCC and SqCC (OR = 2.75 for toenail arsenic concentration ≥0.114 | Toe nail (arsenic) in 4 levels: <0.05 | [ |
†Data from patients from the Blackfoot Disease area in Taiwan.
SCC: small cell carcinoma; NA: data not available; SMR: standardized mortality rate; OR: odds ratios.
Figure 2DNA copy-number alteration at chromosome 9q in arsenic-exposed lung SqCC. CNA frequencies are overlaid in this karyogram. Profiles of 52 lung SqCC biopsies were generated using a submegabase resolution tiling-set rearray (SMRTr) platform. Twenty-two arsenic-exposed samples (shown in red) were obtained from lung cancer patients from northern Chile. Thirty samples from patients without known arsenic exposure (green) were obtained from North American individuals. Regions in yellow denote a sector of overlapping alteration status in both groups. The magnitude of red, green, and yellow bars represents percentage of samples (0–100%, with blue vertical lines representing 50% frequency) exhibiting DNA gains (to the right) and DNA losses (to the left). Dotted line represents 9q12 cytoband.